ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0441

Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort

José Joel Hurtado-Arias1, Isabela Ramírez-Mulhern2, Javier Merayo-Chalico3, Carlos A. Gonzalez-Martinez4, Ana Barrera-Vargas2 and Andrea Hinojosa-Azaola1, 1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 3Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico, 4Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico

Meeting: ACR Convergence 2022

Keywords: ANCA associated vasculitis, Outcome measures, Patient reported outcomes, quality of life, Sexual Function

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – ANCA-Associated Poster I: Epidemiology, Outcomes, and Classification

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The antineutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) are a group of complex chronic diseases resulting in morbidity, accumulated organ damage, treatment burden, and risk of relapses. A key aspect of the outcome measures is to incorporate the patients’ views to determine the impact of the disease. This study aimed to evaluate associations between the domains of the ANCA-associated vasculitis Patient-Reported Outcome (AAV-PRO) instrument and clinical variables.

Methods: Patients with Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA), or renal-limited vasculitis (RLV) according to definitions of the Chapel Hill Consensus Nomenclature and/or the ACR 1990 Classification Criteria were recruited in the Rheumatology consult of a tertiary care center in Mexico City. Demographic, clinical, serologic, and treatment-related variables were retrieved. Disease activity and damage were evaluated with the Birmingham Vasculitis Activity Score for GPA (BVAS/WG) and the Vasculitis Damage Index (VDI), respectively. Patient and Physician Global Assessments (PtGA and PhGA, respectively) in a 0-100 scale were also evaluated. All patients completed the AAV-PRO questionnaire, and sexual function in male patients was assessed with the International Index of Erectile Function (IIEF-5) questionnaire. Descriptive statistics were performed, correlations between variables were calculated using Pearson and Spearman coefficients, whereas differences between groups were analyzed with the Mann-Whitney U test.

Results: Seventy patients (44 women and 26 men) were included, with a median age of 53.5 years (IQR 43-61), disease duration of 82 months (34-135), 58 (83%) had GPA, 5 (7%) EGPA, 5 (7%) RLV, and 2 (3%) MPA diagnosis. Table 1 summarizes the clinical and serologic characteristics, whereas Table 2 depicts the AAV-PRO domains (scales from 0-100 with higher scores representing higher intensity of the symptoms). 17/24 (70.8%) of men who completed the IIEF-5 questionnaire had some degree of erectile dysfunction. Correlations between the clinical variables, outcome measures, and domains of the AAV-PRO are displayed in Table 3. Significant differences were found in the following domains (median (IQR)) of the AAV-PRO according to gender: treatment side effects (20 (10-35) in men vs 35 (17.5-50) in women, p=0.04); age: treatment side effects (40 (25-55) in < 50 years-old vs 20 (10-40) in > 50 years-old, p=0.005), and concerns about the future (55 (45-85) vs 35 (10-70), respectively, p=0.02), and finally, according to disease duration: treatment side effects (40 (25-50) in patients with < 5 years vs 20 (10-45) in those with > 5 years, p=0.03). No correlations were observed between the IIEF-5 score and other variables.

Conclusion: In this cohort of AAV patients with low disease activity, correlations were found between the specific domains of the AAV-PRO and other outcome measures. Differences were found between some of the AAV-PRO domains according to gender, age, and disease duration. It is essential to consider person-centered outcomes in the clinical care of AAV patients.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: J. Hurtado-Arias, None; I. Ramírez-Mulhern, None; J. Merayo-Chalico, Janssen, Sanofi; C. Gonzalez-Martinez, None; A. Barrera-Vargas, AstraZeneca, Sanofi; A. Hinojosa-Azaola, None.

To cite this abstract in AMA style:

Hurtado-Arias J, Ramírez-Mulhern I, Merayo-Chalico J, Gonzalez-Martinez C, Barrera-Vargas A, Hinojosa-Azaola A. Patient-Reported Outcomes in ANCA-Associated Vasculitis: Interactions Between Patients’ and Physicians’ Perspectives in a Mexican Cohort [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/patient-reported-outcomes-in-anca-associated-vasculitis-interactions-between-patients-and-physicians-perspectives-in-a-mexican-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-in-anca-associated-vasculitis-interactions-between-patients-and-physicians-perspectives-in-a-mexican-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology